Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough ...

LISLE, IL, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- OWP Pharmaceuticals today announced commercial product ...

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...

She suffers from adult-onset epilepsy. She had a medical episode at the time of the crash and was driving with a suspended ...

Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.

A 63-year-old man reported that objects -- especially people and faces -- began to appear much smaller than normally expected ...

Seizures in children are usually linked straight away to fever, family history or epilepsy, but doctors still keep running ...

At King Faisal Specialist Hospital & Research Centre (KFSHRC), the treatment of drug-resistant epilepsy has developed over decades into a comprehensive clinical program that combines advanced ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...